NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
0.8480
Dollar change
+0.0559
Percentage change
7.06
%
Index- P/E- EPS (ttm)-0.01 Insider Own16.00% Shs Outstand34.26M Perf Week-2.60%
Market Cap28.98M Forward P/E- EPS next Y-0.14 Insider Trans1.37% Shs Float28.71M Perf Month-10.18%
Enterprise Value24.52M PEG- EPS next Q-0.05 Inst Own20.38% Short Float0.59% Perf Quarter-25.61%
Income-0.55M P/S0.30 EPS this Y-550.00% Inst Trans-24.25% Short Ratio0.78 Perf Half Y-60.56%
Sales97.73M P/B0.92 EPS next Y28.21% ROA-1.06% Short Interest0.17M Perf YTD-58.43%
Book/sh0.92 P/C1.67 EPS next 5Y- ROE-2.12% 52W High5.15 -83.53% Perf Year-51.26%
Cash/sh0.51 P/FCF13.42 EPS past 3/5Y81.27% 66.71% ROIC-1.31% 52W Low0.78 8.70% Perf 3Y-37.65%
Dividend Est.- EV/EBITDA8.92 Sales past 3/5Y17.90% 10.61% Gross Margin17.87% Volatility7.14% 5.63% Perf 5Y-96.15%
Dividend TTM- EV/Sales0.25 EPS Y/Y TTM96.46% Oper. Margin0.59% ATR (14)0.06 Perf 10Y-99.46%
Dividend Ex-Date- Quick Ratio2.50 Sales Y/Y TTM12.82% Profit Margin-0.57% RSI (14)37.64 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio2.95 EPS Q/Q24.75% SMA20-9.22% Beta1.56 Target Price4.00
Payout- Debt/Eq0.41 Sales Q/Q-16.59% SMA50-16.31% Rel Volume1.03 Prev Close0.79
Employees244 LT Debt/Eq0.34 EarningsMay 12 BMO SMA200-59.04% Avg Volume217.97K Price0.85
IPOJan 27, 1998 Option/ShortYes / Yes EPS/Sales Surpr.20.00% 8.33% Trades Volume224,002 Change7.06%
Date Action Analyst Rating Change Price Target Change
Nov-14-24Initiated Rodman & Renshaw Buy $5
Jun-24-19Initiated Piper Jaffray Overweight $10
May-13-19Initiated H.C. Wainwright Buy $11
Nov-08-16Downgrade BofA/Merrill Neutral → Underperform
Mar-01-16Downgrade Stifel Buy → Hold
Aug-13-15Initiated Morgan Stanley Underweight $7
Jan-27-15Reiterated Oppenheimer Outperform $24 → $26
Jan-07-15Initiated Oppenheimer Outperform $24
Aug-14-14Initiated FBR Capital Underperform $6
Dec-19-13Initiated Chardan Capital Markets Buy $22
May-13-25 03:03AM
May-12-25 10:07PM
07:15AM
06:11AM
06:00AM
09:20AM Loading…
May-08-25 09:20AM
Apr-14-25 06:00AM
Mar-21-25 07:08AM
03:02AM
Mar-20-25 11:44PM
09:37AM
09:36AM
07:10AM
06:18AM
06:00AM
06:00PM Loading…
Mar-19-25 06:00PM
Mar-11-25 06:00AM
Feb-27-25 06:00AM
Feb-20-25 06:00AM
Feb-04-25 06:00AM
Dec-17-24 07:51AM
06:00AM
Dec-13-24 03:48PM
12:11PM
Dec-12-24 06:00AM
Dec-05-24 06:00AM
Nov-19-24 06:00AM
Nov-13-24 02:06AM
Nov-12-24 10:01PM
07:10AM
06:12AM Loading…
06:12AM
06:00AM
Nov-11-24 07:21AM
Nov-08-24 07:06AM
06:00AM
Oct-17-24 12:00PM
Oct-14-24 06:00AM
Oct-09-24 05:33PM
Sep-20-24 09:15AM
Sep-18-24 06:00AM
Sep-09-24 12:00PM
08:50AM
06:00AM
Sep-04-24 09:15AM
Sep-03-24 06:00AM
Aug-19-24 09:15AM
Aug-15-24 08:50AM
Aug-08-24 07:15AM
06:13AM
06:00AM
Aug-07-24 06:00AM
Jul-15-24 06:45AM
Jul-11-24 06:00AM
May-30-24 06:00AM
May-15-24 08:19AM
03:01AM
12:37AM
May-14-24 10:54AM
07:15AM
06:11AM
06:00AM
Apr-17-24 06:00AM
Apr-16-24 06:00AM
Apr-04-24 06:00AM
Mar-26-24 06:15PM
Mar-25-24 06:00AM
Mar-22-24 09:52AM
Mar-21-24 09:39PM
10:53AM
07:10AM
06:18AM
06:00AM
Mar-11-24 06:15PM
Mar-05-24 06:00PM
Feb-27-24 06:00PM
Feb-20-24 06:00PM
Feb-14-24 06:00PM
Feb-08-24 06:00AM
Jan-08-24 07:30AM
Nov-15-23 01:29PM
Nov-14-23 10:36PM
07:15AM
06:06AM
06:00AM
Nov-07-23 06:00PM
Oct-26-23 06:00PM
Oct-20-23 06:15PM
Oct-18-23 06:00AM
Oct-17-23 06:00AM
Oct-16-23 06:00AM
Oct-13-23 06:15PM
Oct-03-23 06:15PM
06:00AM
Sep-28-23 06:00AM
Sep-27-23 06:15PM
Sep-21-23 06:15PM
06:30AM
Sep-18-23 11:37AM
Sep-07-23 06:00AM
Aug-15-23 12:29PM
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini on October 25, 1996 and is headquartered in Wixom, MI.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Irrevocable Larson Family Inve10% OwnerApr 10 '25Buy1.0757,00061,0363,527,000Apr 15 02:02 PM
Irrevocable Larson Family Inve10% OwnerApr 11 '25Buy1.0830,50032,9823,557,500Apr 15 02:02 PM
Strobeck MarkPresident and CEOApr 01 '25Sale1.086,9267,480124,678Apr 02 06:06 PM
Neri JesseSVP, FINANCE AND CFOApr 01 '25Sale1.1088697530,000Apr 02 06:05 PM
Chole TimothySVP, Chief Commercial OfficerApr 01 '25Sale1.082,8683,09746,035Apr 02 06:03 PM
Strobeck MarkOfficerApr 01 '25Proposed Sale1.056,9267,263Apr 01 01:49 PM
Chole TimothyOfficerApr 01 '25Proposed Sale1.052,8683,000Apr 01 01:43 PM
Neri JesseOfficerApr 01 '25Proposed Sale1.06886939Apr 01 01:18 PM
Chole TimothySVP, Chief Commercial OfficerJan 02 '25Sale2.051,0012,05254,170Jan 06 04:44 PM
Strobeck MarkPresident and CEOJan 02 '25Sale2.062,1634,445145,038Jan 06 04:43 PM
Strobeck MarkOfficerJan 02 '25Proposed Sale2.062,1634,445Jan 02 03:18 PM
Chole TimothyOfficerJan 02 '25Proposed Sale2.011,0012,015Jan 02 12:40 PM
RAVICH MARK HDirectorNov 15 '24Sale2.3219,99146,3790Nov 19 04:21 PM
RAVICH MARK HDirectorNov 15 '24Sale2.4010,00024,000121,429Nov 19 04:21 PM
Chole TimothySVP, Chief Commercial OfficerOct 01 '24Sale3.691,0013,68955,171Oct 02 09:55 PM
Strobeck MarkPresident and CEOOct 01 '24Sale3.692,1637,971147,201Oct 02 09:54 PM
Strobeck MarkOfficerOct 01 '24Proposed Sale3.652,1637,900Oct 01 02:05 PM
Chole TimothyOfficerOct 01 '24Proposed Sale3.601,0013,600Oct 01 01:36 PM